Aquestive Therapeutics Announces Completion Of Enrollment In Its Oral Allergen Challenge Study For The Development Of Its Late-Stage Pipeline Program, Anaphylm Sublingual Film
Aquestive Therapeutics Announces Completion Of Enrollment In Its Oral Allergen Challenge Study For The Development Of Its Late-Stage Pipeline Program, Anaphylm Sublingual Film
- Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm (epinephrine) Sublingual Film
- Outlines the development strategy for the Company's next pipeline product candidate, AQST-108 (epinephrine) Topical Gel for the treatment of Alopecia areata
- Holds virtual investor day
- 宣佈完成其口服過敏原挑戰研究，用於開發其後期階段管線項目Anaphylm（腎上腺素）舌下膜
- 概述公司下一個管線產品候選AQSt-108（腎上腺素）局部凝膠的發展策略，用於治療斑禿
- 舉辦虛擬投資者日
WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a virtual investor day highlighting the Company's pipeline inclusive of Anaphylm (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both product candidates emerging from the Company's Adrenaverse epinephrine prodrug platform. The event included presentations by members of the Aquestive management team and by distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.
新澤西州禾倫，2024年9月27日（環球新聞社）- Aquestive Therapeutics公司（納斯達克股票代碼：AQST）（"Aquestive"或"公司"），一家藥品公司通過創新科學和傳遞技術推進藥品的研發，以爲患者生活帶來有意義的改善，今日舉辦虛擬投資者日，重點介紹了公司的管線，包括Anaphylm（腎上腺素）舌下膜和AQSt-108（腎上腺素）局部凝膠，這兩個產品候選者均源自公司的Adrenaverse腎上腺素前藥平台。活動包括Aquestive管理團隊成員和著名的意見****，美國德州大學西南醫學中心免疫學/分子生物學副教授的演講。
譯文內容由第三人軟體翻譯。
